PharmaSynergyRx
February 5-6, 2026
London, UK
https://pharma-synergy-conference.com/pharmasynergy-2026/
News and Events
Subscribe to our press distribution list to receive the latest news about AMW.
Downloads
Upcoming
Events
EuroPLX
March 2-3, 2026
Lisbon, Portugal
https://www.raucon.com/euro-plx/euro-p-l-x-90
EAU Congress
March 13-16, 2026
London, UK
https://eaucongress.uroweb.org/
BIO-Europe Spring
March 23-25, 2026
Lisbon, Portugal
https://informaconnect.com/bioeurope-spring/
CPHI South East Asia
July 8-10, 2026
Bangkok, Thailand
https://www.cphi.com/sea/en/attend/attend/why-attend.html
CPHI Milan
October 6-8, 2026
Milan, Italy
https://www.cphi.com/europe/en/exhibit/book-your-stand-milan.html
Past
Events
Archive
DCAT Week 2025
March 17-20, 2025
New York City, USA
https://dcatweek.org/
AT Uro Congress
May 22-24, 2025
Vienna, Austria
International Partnering in Life-Sciences Society (IPLS)
September 29 – October 1, 2025
Berlin, Germany
https://ipls.online/events/
PODD – Partnership Opportunities in Drug Delivery
October 27-28, 2025
Boston, US
https://poddconference.com/
CPHI Frankfurt
October 28-30, 2025
Frankfurt, Germany
https://www.cphi.com/europe/en/home.html
BIO-Europe
November 3-5, 2025
Vienna, Austria
https://informaconnect.com/bioeurope/
Latest
News
BfArM approvals from DCP procedure for Rivastigmin patches granted for Germany, Austria, Romania, Sweden, Slovakia and the Czech Republic
On 28 August 2015, the BfArM granted approvals from DCP procedures for rivastigmin patches at doses 4.6 mg/24 h and 9.5 mg/24 h for Germany, Austria, Romania, Sweden, Slovakia and the Czech Republic.
read moreSuccessful financing round for pharmaceutical company AMW
AMW GmbH (Arzneimittelwerk Warngau) has received follow-on financing to advance the development and commercialization process for its drug delivery systems. Together with BayBG Bayerische Beteiligungsgesellschaft, UnternehmerTUM-Fonds and IBG Beteiligungsgesellschaft, the existing investors are putting in a total of up to seven million euros. The funds will be used for the marketing of the existing product portfolio and the development of a new technology for the controlled release of pharmaceuticals. AMW GmbH produces active ingredient implants as well as transdermal systems in the fast-growing fields of oncology, pain therapy and neurology.
read moreAMW GmbH announces that another round of financing has been concluded with the existing shareholders.
AMW GmbH announces that another round of financing has been concluded with the existing shareholders. The funds are used to strengthen further growth and the development of innovative products. Dr. Wilfried Fischer, managing director of AMW GmbH, thanks for the trust of the shareholders in the performance of the company.
read moreIn January 2014, AMW GmbH was able to conclude a semi-exclusive license and supply contract for its biodegradable goserelin implants with a multinational pharmaceutical company.
The contract applies to Southeast Asia, including China, Eastern Europe, Russia and some Western European countries. The agreements contain down payment payments of up to € 10 million, license payments in the double-digit percentage range, and an exclusive delivery agreement for AMW. The partner company will carry out further clinical developments for the contract area.
read moreAMW GmbH has been successfully certified by Tüv Süd to EN ISO 13485: 2012/AC: 2012
Nr.ISO Certificate: Q21-13.07.84140.001
Validity: from 07.10.2013 to 06.10.2016
Scope: Manufacture, quality control, quality assurance and distribution of medical devices in plaster form
Applied standard(s):
EN ISO 13485: 2012/AC: 2012
Medical devices
Quality management systems
Requirements for regulatory purposes